Pacific Biosciences
PACB
PACB
225 hedge funds and large institutions have $1.23B invested in Pacific Biosciences in 2022 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 64 increasing their positions, 67 reducing their positions, and 40 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
4% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 67
6.25% less ownership
Funds ownership: 100.46% → 94.21% (-6.3%)
42% less call options, than puts
Call options by funds: $11.6M | Put options by funds: $20M
Holders
225
Holding in Top 10
3
Calls
$11.6M
Puts
$20M
Top Buyers
| 1 | +$26.8M | |
| 2 | +$17.4M | |
| 3 | +$14.7M | |
| 4 |
DM
Deerfield Management
New York
|
+$11.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$4.13M |
Top Sellers
| 1 | -$40.2M | |
| 2 | -$27.8M | |
| 3 | -$25.1M | |
| 4 |
Two Sigma Investments
New York
|
-$19.8M |
| 5 |
Capital International Investors
Los Angeles,
California
|
-$18.1M |